Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtre
1.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 41(5): 419-427, Sept.-Oct. 2019. tab, graf
Article Dans Anglais | LILACS | ID: biblio-1039115

Résumé

Objective: To evaluate whether an animal model of mania induced by lisdexamfetamine dimesylate (LDX) has an inflammatory profile and whether immune activation by lipopolysaccharides (LPS) has a cumulative effect on subsequent stimuli in this model. We also evaluated the action of lithium (Li) on inflammatory and neurotrophic factors. Methods: Adult male Wistar rats were subjected to an animal model of mania. After the open-field test, they were given LPS to induce systemic immune activation. Subsequently, the animals' blood was collected, and their serum levels of brain-derived neurotrophic factor and inflammatory markers (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-1β, IL-10, and inducible nitric oxide synthase [iNOS]) were measured. Results: LDX induced hyperactivity in the animals, but no inflammatory marker levels increased except brain-derived neurotrophic factor (BDNF). Li had no effect on serum BDNF levels but prevented iNOS levels from increasing in animals subjected to immune activation. Conclusion: Although Li prevented an LPS-induced increase in serum iNOS levels, its potential anti-inflammatory effects in this animal model of mania were conflicting.


Sujets)
Animaux , Mâle , Trouble bipolaire/immunologie , Modèles animaux de maladie humaine , Dimésylate de lisdexamfétamine , Lithium/pharmacologie , Anti-inflammatoires/pharmacologie , Facteurs de croissance nerveuse/effets des médicaments et des substances chimiques , Facteurs temps , Trouble bipolaire/physiopathologie , Trouble bipolaire/induit chimiquement , Test ELISA , Lipopolysaccharides/pharmacologie , Reproductibilité des résultats , Cytokines/sang , Résultat thérapeutique , Rat Wistar , Facteur neurotrophique dérivé du cerveau/sang , Nitric oxide synthase type II/sang , Locomotion/effets des médicaments et des substances chimiques
2.
Acta cir. bras ; 34(12): e201901205, 2019. graf
Article Dans Anglais | LILACS | ID: biblio-1054687

Résumé

Abstract Purpose To investigate the effects of huperzine A (HupA) on hippocampal inflammatory response and neurotrophic factors in aged rats after anesthesia. Methods Thirty-six Sprague Dawley rats (20-22 months old) were randomly divided into control, isofluran, and isoflurane+HupA groups; 12 rats in each group. The isoflurane+HupA group was intraperitoneally injected with 0.2 mg/kg of HupA. After 30 min, isoflurane inhalation anesthesia was performed in the isoflurane and isoflurane+HupA groups. After 24 h from anesthesia, Morris water maze experiment and open-field test were performed. Hippocampal inflammatory and neurotrophic factors were determined. Results Compared with isoflurane group, in isofluran+HupA group the escape latency of rats was significantly decreased (P < 0.05), the original platform quadrant residence time and traversing times were significantly increased (P < 0.05), the central area residence time was significantly increased (P < 0.05), the hippocampal tumor necrosis factor α, interleukin 6 and interleukin 1β levels were significantly decreased (P < 0.05), and the hippocampal nerve growth factor, brain derived neurotrophic factor and neurotrophin-3 levels were significantly increased (P < 0.05). Conclusion HupA may alleviate the cognitive impairment in rats after isoflurane anesthesia by decreasing inflammatory factors and increasing hippocampal neurotrophic factors in hippocampus tissue.


Sujets)
Humains , Animaux , Mâle , Sesquiterpènes/pharmacologie , Neuroprotecteurs/pharmacologie , Anesthésiques par inhalation/effets indésirables , Alcaloïdes/pharmacologie , Hippocampe/effets des médicaments et des substances chimiques , Facteurs de croissance nerveuse/effets des médicaments et des substances chimiques , Test ELISA , Répartition aléatoire , Reproductibilité des résultats , Interleukine-6/analyse , Rat Sprague-Dawley , Apprentissage du labyrinthe , Interleukine-1 bêta/analyse , Hippocampe/métabolisme , Isoflurane/effets indésirables , Anesthésie/effets indésirables , Facteurs de croissance nerveuse/analyse
3.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 40(4): 367-375, Oct.-Dec. 2018. graf
Article Dans Anglais | LILACS | ID: biblio-959251

Résumé

Objective: To evaluate the effects of Hypericum perforatum (hypericum) on cognitive behavior and neurotrophic factor levels in the brain of male and female rats. Methods: Male and female Wistar rats were treated with hypericum or water during 28 days by gavage. The animals were then subjected to the open-field test, novel object recognition and step-down inhibitory avoidance test. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-line derived neurotrophic factor (GDNF) levels were evaluated in the hippocampus and frontal cortex. Results: Hypericum impaired the acquisition of short- and long-term aversive memory in male rats, evaluated in the inhibitory avoidance test. Female rats had no immediate memory acquisition and decreased short-term memory acquisition in the inhibitory avoidance test. Hypericum also decreased the recognition index of male rats in the object recognition test. Female rats did not recognize the new object in either the short-term or the long-term memory tasks. Hypericum decreased BDNF in the hippocampus of male and female rats. Hypericum also decreased NGF in the hippocampus of female rats. Conclusions: The long-term administration of hypericum appears to cause significant cognitive impairment in rats, possibly through a reduction in the levels of neurotrophic factors. This effect was more expressive in females than in males.


Sujets)
Animaux , Mâle , Femelle , Extraits de plantes/pharmacologie , Cognition/effets des médicaments et des substances chimiques , Hypericum , Lobe frontal/métabolisme , Hippocampe/métabolisme , Facteurs de croissance nerveuse/analyse , Extraits de plantes/administration et posologie , Répartition aléatoire , Facteurs sexuels , Résultat thérapeutique , Rat Wistar , Modèles animaux , Reconnaissance physiologique des formes/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Lobe frontal/effets des médicaments et des substances chimiques , Hippocampe/effets des médicaments et des substances chimiques , Locomotion/effets des médicaments et des substances chimiques , Mémoire/effets des médicaments et des substances chimiques , Facteurs de croissance nerveuse/effets des médicaments et des substances chimiques
4.
Braz. j. med. biol. res ; 45(3): 230-237, Mar. 2012. ilus
Article Dans Anglais | LILACS | ID: lil-618046

Résumé

Doxorubicin (DOX) was conjugated to a single-chain variable fragment (scFv) against human midkine (MK), and the conjugate (scFv-DOX) was used to target the chemotherapeutic agent to a mouse solid tumor model in which the tumor cells expressed high levels of human MK. The His-tagged recombinant scFv was expressed in bacteria, purified by metal affinity chromatography, and then conjugated to DOX using oxidative dextran (Dex) as a linker. The molecular formula of this immunoconjugate was scFv(Dex)1.3(DOX)20. In vitro apoptosis assays showed that the scFv-DOX conjugate was more cytotoxic against MK-transfected human adenocarcinoma cells (BGC823-MK) than untransfected cells (55.3 ± 2.4 vs 22.4 ± 3.8 percent) for three independent experiments. Nude mice bearing BGC823-MK solid tumors received scFv-DOX or equivalent doses of scFv + DOX for 2 weeks and tumor growth was more effectively inhibited by the scFv-DOX conjugate than by scFv + DOX (51.83 percent inhibition vs 40.81 percent). Histological analysis of the tumor tissues revealed that the highest levels of DOX accumulated in tumors from mice treated with scFv-DOX and this resulted in more extensive tumor cell death than in animals treated with the equivalent dose of scFv + DOX. These results show that the scFv-DOX conjugate effectively inhibited tumor growth in vivo and suggest that antigen-specific scFv may be competent drug-carriers.


Sujets)
Animaux , Femelle , Humains , Souris , Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Cytokines/immunologie , Doxorubicine/pharmacologie , Immunoconjugués/pharmacologie , Anticorps à chaîne unique , Antinéoplasiques/composition chimique , Cytokines/métabolisme , Tests de criblage d'agents antitumoraux , Doxorubicine/composition chimique , Immunoconjugués/composition chimique , Souris de lignée BALB C , Souris nude , Facteurs de croissance nerveuse/effets des médicaments et des substances chimiques , Cellules cancéreuses en culture
5.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 30(4): 337-340, Dec. 2008. graf, tab
Article Dans Anglais | LILACS | ID: lil-501864

Résumé

OBJECTIVE: The neurotrophins, antioxidant enzymes and oxidative markers have reciprocal interactions. This report verified in chronically stable medicated schizophrenic patients whether there are correlations between the serum levels of superoxide dismutase, a key enzyme in the antioxidant defense, thiobarbituric acid reactive substances, a direct index of lipid peroxidation, and brain-derived neurotrophic factor, the most widely distributed neurotrophin. METHOD: Sixty DSM-IV schizophrenic patients were included (43 males, 17 females). Mean age was 34.7 ± 10.8 years, mean age at first episode was 19.8 ± 7.9 years, and mean illness duration was 14.9 ± 8.5 years. Each subject had a blood sample collected for the determination of serum levels of brain-derived neurotrophic factor, thiobarbituric acid reactive substances and superoxide dismutase. RESULTS: Brain-derived neurotrophic factor levels showed a positive correlation with thiobarbituric acid reactive substances levels (r = 0.333, p = 0.009). Brain-derived neurotrophic factor levels were not correlated with superoxide dismutase levels (r = - 0.181, p = 0.166), and superoxide dismutase levels were not correlated with thiobarbituric acid reactive substances levels (r = 0.141, p = 0.284). CONCLUSIONS: The positive correlation between brain-derived neurotrophic factor and thiobarbituric acid reactive substances suggests the need of further investigation on intracellular interactions of neurotrophins, antioxidant enzymes and oxidative markers. In addition, this opens a venue for investigation on treatments for the prevention of neurotoxicity along the course of schizophrenia.


OBJETIVO: As neurotrofinas, enzimas antioxidantes e marcadores de oxidação têm interações. Este estudo verificou se existem correlações entre os níveis séricos de superóxido-dismutase, uma enzima chave na defesa antioxidante, os produtos de reação com o ácido tiobarbitúrico, um indicador direto de peroxidação lipídica, e o fator neurotrófico derivado do cérebro, a neurotrofina mais amplamente distribuída. MÉTODO: Sessenta pacientes portadores de Esquizofrenia pelo DSM-IV foram incluídos (43 homens, 17 mulheres), com idade média de 34,7 ± 10,8 anos, idade média no primeiro episódio de 19,8 ± 7,9 anos, e tempo médio de duração da doença de 14,9 ± 8,5 anos. Foi coletado sangue de cada sujeito para a determinação dos níveis séricos de fator neurotrófico derivado do cérebro, superóxido-dismutase e ácido tiobarbitúrico. RESULTADOS: Os níveis de fator neurotrófico derivado do cérebro se correlacionaram positivamente aos de ácido tiobarbitúrico (r = 0,333, p = 0,009) e não mostraram correlação com os de superóxido-dismutase (r = - 0,181, p = 0,166). Este último também não se correlacionou aos níveis de ácido tiobarbitúrico (r = 0,141, p = 0,284). CONCLUSÕES: A correlação positiva entre fator neurotrófico derivado do cérebro e ácido tiobarbitúrico direciona para investigações na interação intracelular entre neurotrofinas, enzimas antioxidantes e marcadores de oxidação, além de abrir perspectives para pesquisa em tratamentos para a prevenção da neurotoxicidade ao longo do curso da esquizofrenia.


Sujets)
Adulte , Femelle , Humains , Mâle , Neuroleptiques/usage thérapeutique , Facteur neurotrophique dérivé du cerveau/sang , Schizophrénie/sang , Superoxide dismutase/sang , Substances réactives à l'acide thiobarbiturique/analyse , Maladie chronique , Études de cohortes , Facteurs de croissance nerveuse/effets des médicaments et des substances chimiques , Facteurs de croissance nerveuse/métabolisme , Schizophrénie/traitement médicamenteux
SÉLECTION CITATIONS
Détails de la recherche